Seminars in Oncology
Volume 31, Issue 4 , Pages 487-497 , August 2004

Screening for upper gastrointestinal tract malignancies

  • Alphonso Brown

      Affiliations

    • Center for Gastrointestinal Biology and Disease, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    • Corresponding Author InformationAddress reprint requests to Alphonso Brown, MD, CB#7080, UNC-CH, Chapel Hill, NC 27599-7080 USA
    • ,
  • Nicholas J. Shaheen

      Affiliations

    • Center for Gastrointestinal Biology and Disease, University of North Carolina School of Medicine, Chapel Hill, NC, USA

References 

  1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33–64
  2. Jemal A, Murray T, Samuels A, et al.  Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26
  3. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053
  4. Schoenberg BS, Bailar JC, Fraumeni JF. Certain mortality patterns of esophageal cancer in the United States, 1930–67. J Natl Cancer Inst. 1971;46:63–73
  5. Guanrei Y, Songliang Q, He H, et al.  Natural history of early esophageal squamous carcinoma and early adenocarcinoma of the gastric cardia in the People’s Republic of China. Endoscopy. 1988;20:95–98
  6. Crespi M, Munoz N, Grassi A, et al.  Oesophageal lesions in northern Iran (A premalignant condition?). Lancet. 1979;2:217–221
  7. Shen Q, Liu SF, Dawsey SM. Cytological screening for esophageal cancer (Results from 12,877 subjects from a high-risk population in China). Int J Cancer. 1993;54:185–188
  8. Guanrei Y, He H, Sungliang Q, et al.  Endoscopic diagnosis of 115 cases of early esophageal carcinoma. Endoscopy. 1982;14:157–161
  9. Tsang TK, Hidvegi D, Horth K, et al.  Reliability of balloon-mesh cytology in detecting esophageal carcinoma in a population of US veterans. Cancer. 1987;59:556–559
  10. Jacob P, Kahrilas PJ, Desai T, et al.  Natural history and significance of esophageal squamous cell dysplasia. Cancer. 1990;65:2731–2739
  11. Graham DY, Schwartz JT, Cain GD, et al.  Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology. 1982;82:228–231
  12. Chisholm EM, Williams SR, Leung JW, et al.  Lugol’s iodine dye-enhanced endoscopy in patients with cancer of the oesophagus and head and neck. Eur J Surg Oncol. 1992;18:550–552
  13. Dawsey SM, Wang GQ, Weinstein WM, et al.  Squamous dysplasia and early esophageal cancer in the Linxian region of China (Distinctive endoscopic lesions). Gastroenterology. 1993;105:1333–1340
  14. Nishizawa M, Okada T, Hosoi T, et al.  Detecting early esophageal cancers, with special reference to the intraepithelial stage. Endoscopy. 1984;16:92–94
  15. Adachi Y, Kitamura K, Tsutsui S, et al.  How to detect early carcinoma of the esophagus. Hepatogastroenterology. 1993;40:207–211
  16. Munck-Wikland E, Kuylenstierna R, Wahren B, et al.  Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer. 1988;62:2281–2286
  17. McKnight A, Mannell A, Shperling I. The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancer. Br J Cancer. 1989;60:249–251
  18. Gion M, Mione R, Tremolada C, et al.  Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma. Scand J Clin Lab Invest. 1991;207(suppl):37–41
  19. Dowlatshahi K, Mehta RG, Levin B, et al.  Retinoic-acid-binding protein in normal and neoplastic human esophagus. Cancer. 1984;54:308–311
  20. The role of endoscopy in the surveillance of premalignant conditions of the upper gastrointestinal tract. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc. 1998;48:663–668
  21. MacDonald WC, MacDonald JB. Adenocarcinoma of the esophagus and/or gastric cardia. Cancer. 1987;60:1094–1098
  22. Bollschweiler E, Wolfgarten E, Gutschow C, et al.  Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92:549–555
  23. Cameron AJ, Lomboy CT, Pera M, et al.  Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology. 1995;109:1541–1546
  24. Hameeteman W, Tytgat GN, Houthoff HJ, et al.  Barrett’s esophagus (Development of dysplasia and adenocarcinoma). Gastroenterology. 1989;96:1249–1256
  25. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett’s oesophagus. Gut. 1991;32:1441–1446
  26. Iftikhar SY, James PD, Steele RJ, et al.  Length of Barrett’s oesophagus (An important factor in the development of dysplasia and adenocarcinoma). Gut. 1992;33:1155–1158
  27. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett’s esophagus (A prospective study of 170 patients followed 4.8 years). Am J Gastroenterol. 1997;92:212–215
  28. O’Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus (Report on the Cleveland Clinic Barrett’s Esophagus Registry). Am J Gastroenterol. 1999;94:2037–2042
  29. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett’s esophagus (A prospective controlled investigation). Am J Med. 2001;111:33–37
  30. Bani-Hani K, Sue-Ling H, Johnston D, et al.  Barrett’s oesophagus (Results from a 13-year surveillance programme). Eur J Gastroenterol Hepatol. 2000;12:649–654
  31. Lagergren J, Bergstrom R, Adami HO, et al.  Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000;133:165–175
  32. Cameron AJ, Lomboy CT. Barrett’s esophagus (Age, prevalence, and extent of columnar epithelium). Gastroenterology. 1992;103:1241–1245
  33. Reid BJ, Levine DS, Longton G, et al.  Predictors of progression to cancer in Barrett’s esophagus (Baseline histology and flow cytometry identify low- and high-risk patient subsets). Am J Gastroenterol. 2000;95:1669–1676
  34. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med. 1985;313:857–859
  35. Lagergren J, Bergstrom R, Lindgren A, et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831
  36. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883–890
  37. Gray MR, Donnelly RJ, Kingsnorth AN. The role of smoking and alcohol in metaplasia and cancer risk in Barrett’s columnar lined oesophagus. Gut. 1993;34:727–731
  38. Freedman J, Ye W, Naslund E, et al.  Association between cholecystectomy and adenocarcinoma of the esophagus. Gastroenterology. 2001;121:548–553
  39. Berenson MM, Riddell RH, Skinner DB, et al.  Malignant transformation of esophageal columnar epithelium. Cancer. 1978;41:554–561
  40. Phillips RW, Wong RK. Barrett’s esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am. 1991;20:791–816
  41. Cameron AJ, Zinsmeister AR, Ballard DJ, et al.  Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology. 1990;99:918–922
  42. Pellegrini CA, Pohl D. High-grade dysplasia in Barrett’s esophagus (Surveillance or operation?). J Gastrointest Surg. 2000;4:131–134
  43. Buttar NS, Wang KK, Sebo TJ, et al.  Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120: 1630–169
  44. Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus (A new look at surveillance based on emerging estimates of cancer risk). Am J Gastroenterol. 1999;94:2043–2053
  45. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease (Is it cost-effective?). Am J Gastroenterol. 2000;95:2086–2093
  46. Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett’s esophagus in the United States. Gastrointest Endosc. 2000;52:197–203
  47. Peters FT, Ganesh S, Kuipers EJ, et al.  Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. Gut. 1999;45:489–494
  48. Cooper BT, Neumann CS, Cox MA, et al.  Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett’s oesophagus. Aliment Pharmacol Ther. 1998;12:893–897
  49. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett’s esophagus. Am J Gastroenterol. 1997;92:582–585
  50. Spechler SJ, Lee E, Ahnen D, et al.  Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease (Follow-up of a randomized controlled trial). JAMA. 2001;285: 2331–2238
  51. Schnell TG, Sontag SJ, Chejfec G, et al.  Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–1619
  52. Falk GW, Catalano MF, Sivak MV, et al.  Endosonography in the evaluation of patients with Barrett’s esophagus and high-grade dysplasia. Gastrointest Endosc. 1994;40:207–212
  53. Scotiniotis IA, Kochman ML, Lewis JD, et al.  Accuracy of EUS in the evaluation of Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc. 2001;54:689–696
  54. Stevens PD, Lightdale CJ, Green PH, et al.  Combined magnification endoscopy with chromoendoscopy for the evaluation of Barrett’s esophagus. Gastrointest Endosc. 1994;40:747–749
  55. Sharma P, Weston AP, Topalovski M, et al.  Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s oesophagus. Gut. 2003;52:24–27
  56. Ofman JJ, Lewin K, Ramers C, et al.  The economic impact of the diagnosis of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2000;95:2946–2952
  57. Skacel M, Petras RE, Rybicki LA, et al.  p53 expression in low grade dysplasia in Barrett’s esophagus (Correlation with interobserver agreement and disease progression). Am J Gastroenterol. 2002;97:2508–2513
  58. Skacel M, Petras RE, Gramlich TL, et al.  The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95:3383–3387
  59. Weston AP, Banerjee SK, Sharma P, et al.  p53 protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus (Immunohistochemical marker predictive of progression). Am J Gastroenterol. 2001;96:1355–1362
  60. Pisani P, Parkin DM, Bray F, et al.  Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18–29
  61. Parker SL, Tong T, Bolden S, et al.  Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5–27
  62. Curtis RE, Kennedy BJ, Myers MH, et al.  Evaluation of AJC stomach cancer staging using the SEER population. Semin Oncol. 1985;12:21–31
  63. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48:3554–3560
  64. Eslick GD, Lim LL, Byles JE, et al.  Association of Helicobacter pylori infection with gastric carcinoma (A meta-analysis). Am J Gastroenterol. 1999;94:2373–2379
  65. Elsborg L, Mosbech J. Pernicious anaemia as a risk factor in gastric cancer. Acta Med Scand. 1979;206:315–318
  66. Stalnikowicz R, Benbassat J. Risk of gastric cancer after gastric surgery for benign disorders. Arch Intern Med. 1990;150:2022–2026
  67. Tersmette AC, Offerhaus GJ, Tersmette KW, et al.  Meta-analysis of the risk of gastric stump cancer (Detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions). Cancer Res. 1990;50:6486–6489
  68. Nakamura T, Nakano G. Histopathological classification and malignant change in gastric polyps. J Clin Pathol. 1985;38:754–764
  69. Zullo A, Romiti A, Rinaldi V, et al.  Gastric pathology in patients with common variable immunodeficiency. Gut. 1999;45:77–81
  70. You WC, Ma JL, Liu W, et al.  Blood type and family cancer history in relation to precancerous gastric lesions. Int J Epidemiol. 2000;29:405–407
  71. Zhang ZF, Kurtz RC, Yu GP, et al.  Adenocarcinomas of the esophagus and gastric cardia (the role of diet). Nutr Cancer. 1997;27:298–309
  72. Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet. 1988;1:1149–1151
  73. Vasen HF, Wijnen JT, Menko FH, et al.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110:1020–1027
  74. Kawai K, Watanabe Y. The impact of mass screening on gastric cancer mortality in Japan. Gastrointest Endosc. 1998;47:320–323
  75. Llorens P. Gastric cancer mass survey in Chile. Semin Surg Oncol. 1991;7:339–343
  76. Guilford P, Hopkins J, Harraway J, et al.  E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–405
  77. Keller G, Vogelsang H, Becker I, et al.  Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155:337–342
  78. Yoon KA, Ku JL, Yang HK, et al.  Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet. 1999;44:177–180
  79. Richards FM, McKee SA, Rajpar MH, et al.  Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet. 1999;8:607–610
  80. Shinmura K, Kohno T, Takahashi M, et al.  Familial gastric cancer (Clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations). Carcinogenesis. 1999;20:1127–1131
  81. Chun YS, Lindor NM, Smyrk TC, et al.  Germline E-cadherin gene mutations (Is prophylactic total gastrectomy indicated?). Cancer. 2001;92:181–187
  82. Ikeguchi M, Saito H, Katano K, et al.  Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci. 1998;43:964–970
  83. Ohta M, Inoue H, Cotticelli MG, et al.  The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84:587–597
  84. Nakatsuru S, Yanagisawa A, Ichii S, et al.  Somatic mutation of the APC gene in gastric cancer (Frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma). Hum Mol Genet. 1992;1:559–563
  85. Fang DC, Jass JR, Wang DX. Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer. J Clin Pathol. 1998;51:593–596
  86. Ristimaki A, Honkanen N, Jankala H, et al.  Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–1280
  87. Park WS, Oh RR, Kim YS, et al.  Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. APMIS. 2000;108:195–200
  88. Maeda K, Chung YS, Ogawa Y, et al.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77:858–863
  89. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:1028–1032
  90. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer (Scientific review). JAMA. 2002;287:1972–1981

☆ Supported by the Robert Wood Johnson Minority Medical Faculty Development Program and National Institutes of Health Grant No. K23 DK59311.

PII: S0093-7754(04)00239-8

doi: 10.1053/j.seminoncol.2004.04.018

Seminars in Oncology
Volume 31, Issue 4 , Pages 487-497 , August 2004

Article Tools